dr. oh on the enzamet trial in mhspc
Published 4 years ago • 80 plays • Length 2:09Download video MP4
Download video MP3
Similar videos
-
1:02
dr. oh on choosing ar-targeted therapy versus chemotherapy in mhspc
-
0:53
dr. oh on the sequencing of new therapies for prostate cancer
-
1:56
dr. oh on targeted treatment in metastatic castration-resistant prostate cancer
-
1:12
dr. oh on the management of hormone-sensitive prostate cancer
-
1:36
dr. oh on results of chemotherapy versus arta in prostate cancer
-
6:05
enzamet trial
-
1:43
dr. oh on the role of docetaxel in metastatic hormone-sensitive prostate cancer
-
1:15
dr. oh on the hormone-sensitive setting in prostate cancer
-
1:29
dr. oh on recognizing symptom burden in advanced prostate cancer
-
6:02
update on the arches trial: new indication for enzalutamide in mhspc
-
1:17
dr. oh on the safety profile of docetaxel in prostate cancer
-
2:47
enzamet trial: early enzalutamide delays progression, improves survival in mhspc
-
2:46
dr. sweeney on the phase iii enzamet trial in metastatic hormone-sensitive prostate cancer
-
1:37
dr. oh discusses the use of abiraterone and docetaxel in prostate cancer
-
1:02
dr. oh discusses the role of chemotherapy in prostate cancer
-
0:51
dr. gomella on the fda approval of enzalutamide in nonmetastatic crpc
-
1:48
dr. oh discusses immunotherapy in prostate cancer
-
1:41
dr. oh on abiraterone versus docetaxel in prostate cancer
-
5:11
enzalutamide adt in men with de novo mhspc: the arches trial